Gilead Sciences, Inc (NASDAQ:GILD)’s traded shares stood at 3.68 million during the latest session, with the company’s beta value hitting 0.20. At the last check today, the stock’s price was $93.86, to imply an increase of 2.48% or $2.27 in intraday trading. The GILD share’s 52-week high remains $98.90, putting it -5.37% down since that peak but still an impressive 33.87% since price per share fell to its 52-week low of $62.07. The company has a valuation of $116.98B, with an average of 5.76 million shares in intraday trading volume over the past 10 days and average of 6.76 million shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Gilead Sciences, Inc (GILD), translating to a mean rating of 1.97. Of 17 analyst(s) looking at the stock, 0 analyst(s) give GILD a Sell rating. 0 of those analysts rate the stock as Overweight while 6 advise Hold as 11 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 1.72.

Gilead Sciences, Inc (NASDAQ:GILD) trade information

After registering a 2.48% upside in the latest session, Gilead Sciences, Inc (GILD) has traded red over the past five days. The 5-day price performance for the stock is 1.57%, and 4.04% over 30 days. With these gigs, the year-to-date price performance is 15.87%. Short interest in Gilead Sciences, Inc (NASDAQ:GILD) saw shorts transact 18.06 million shares and set a 2.65 days time to cover.

The extremes give us $71 and $105 for target low and target high price respectively. As such, GILD has been trading -11.87% off suggested target high and 24.36% from its likely low.

Gilead Sciences, Inc (GILD) estimates and forecasts

Looking at statistics comparing Gilead Sciences, Inc share performance against respective industry, we note that the company has underperformed competitors. Gilead Sciences, Inc (GILD) shares are 47.01% up over the last 6 months, with its year-to-date growth rate lower than industry average at -35.71% against 17.40%. The rating firms project that company’s revenue will grow 4.39% compared to the previous financial year.

Revenue forecast for the current quarter as set by 22 analysts is 7.16B. Meanwhile, for the current quarter, a total of 8 analyst(s) estimate revenue growth to 6.64B.Earnings reports from the last fiscal year show that sales brought in 7.12B and 6.69B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 0.67% before dropping -0.67% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 1.55% for the past 5-year period. While 2024 is set for a -34.68% return in earnings, projections for the next 5 years are at 7.50% annually.

GILD Dividends

Gilead Sciences, Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Gilead Sciences, Inc has a forward dividend ratio of 3.06, with the share yield ticking at 3.26% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 4.02%.

Gilead Sciences, Inc (NASDAQ:GILD)’s Major holders

Gilead Sciences, Inc insiders hold 0.12% of total outstanding shares, with institutional holders owning 88.40% of the shares at 88.51% float percentage. In total, 88.40% institutions holds shares in the company, led by BLACKROCK INC. As of 2024-06-30, the company held over 120.63 million shares (or 9.6738% of shares), all amounting to roughly $8.28 billion.

The next major institution holding the largest number of shares is VANGUARD GROUP INC with 115.26 million shares, or about 9.2431% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $7.91 billion.